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Plain language summary
Little is known about recovery patterns from acute exacerbations of chronic obstructive
pulmonary disease (AECOPD) in newly diagnosed or maintenance treatment-naïve patients.
This study examined this process in patients with moderate-to-severe COPD with an acute
respiratory tract infection (RTI) enrolled in a 12-week, randomized clinical trial (TICARI 1;
NCT01483625), originally designed to examine the efficacy and safety of once-daily tiotropium 18 µg in this population. Symptomatic recovery was assessed using the EXAcerbation
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Background: Little is known about the recovery patterns from acute exacerbations of chronic
obstructive pulmonary disease (AECOPD) in newly diagnosed or maintenance treatment-naïve
patients with COPD. This study describes the course of AECOPD in these patients at the time
of treatment for the symptoms of acute respiratory tract infection (RTI).
Methods: This study was a secondary analysis of data from a 12-week, randomized clinical
trial (TICARI 1) testing the efficacy and safety of once-daily tiotropium 18 µg maintenance
therapy versus placebo in newly diagnosed or maintenance treatment-naïve COPD patients
with acute RTI symptoms for #7 days. Patients received standard care for AECOPD and RTI.
Due to under-recruitment, the trial ended early and hence was underpowered to detect treatment differences. Data were pooled and exacerbation recovery patterns examined by using the
EXAcerbation of Chronic Pulmonary Disease Tool (EXACT), forced expiratory volume in
1 second, rescue medication use, COPD Assessment Test™, Functional Assessment of Chronic
Illness Therapy–Short Form, and Work Productivity and Activity Impairment Questionnaire:
Respiratory Symptoms.
Results: Of 140 patients, 73.6% had a prior COPD diagnosis without maintenance therapy;
80.0% had moderate-to-severe airflow obstruction. In addition to study drug, 40.0% were
prescribed pharmacologic therapy (corticosteroids [34.3%], antibiotics [16.4%], and shortacting β2-adrenergic agonists [5.0%]) within ±7 days of randomization. Over 12 weeks, 78.6%
exhibited symptomatic recovery (EXACT score) in a median of 5.0 days. Across all patients,
49.3% recovered without relapse, 29.3% recovered and then relapsed, and 21.4% had persistent
symptoms (recovery criteria unmet).
Conclusion: A substantial portion of newly diagnosed or maintenance treatment-naïve patients
with COPD experience relapse or persistent symptoms following a clinic visit for AECOPD
with symptoms of RTI. Whether initiating maintenance therapy could improve outcomes and
reduce exacerbation risk requires further study.
Keywords: acute respiratory tract infection symptoms, acute exacerbation of chronic obstructive pulmonary disease, AECOPD, COPD Assessment Test™, EXACT, maintenance therapy,
pulmonary function, tiotropium
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of Chronic Pulmonary Disease Tool (EXACT), a 14-item diary
completed by patients each evening, to assess the severity of breathlessness, cough, sputum, chest symptoms, sleep disturbance, feeling
week or tired, and feeling worried or concerned. Over 12 weeks,
49.3% of patients recovered without a relapse, 29.3% recovered
and subsequently relapsed, and 21.4% had persistent symptoms
(ie, did not meet the recovery criteria). Results were consistent
across health outcomes, including health status, dyspnea, activity
limitation, and work productivity. The study findings suggest that a
significant portion of newly diagnosed and treatment-naïve patients
have difficulty recovering from an acute RTI. Further study of the
short- and long-term effects of these events and the effectiveness
of various treatment options is warranted.

Introduction
Chronic obstructive pulmonary disease (COPD) is often undetected or under-diagnosed until it has progressed to more
advanced stages.1 This may be due, in part, to difficulty
recognizing that the symptoms, such as cough, sputum production, and/or shortness of breath, may signal respiratory
impairment in need of diagnosis and treatment. Patients may
underestimate or understate their symptoms, assuming that
they are due to normal aging, body weight, smoking, or other
factors. Progressive airflow limitation may only become
evident to the patient and clinician when the respiratory
system is challenged by an acute respiratory tract infection
(RTI). These events can be viewed as opportunities for
clinicians to diagnose COPD and to initiate maintenance
therapy in patients who are more aware of their condition
and are at risk for repeated acute exacerbations of COPD
(AECOPD).2–5
Little is known about AECOPD and the effect of treatment in newly diagnosed and treatment-naïve patients with
COPD. In studies of patients with an established COPD
diagnosis, recovery times have been shown to be longer
in individuals with moderate-to-severe airflow obstruction
who have more pronounced decline in lung function during
the event and, in some cases, recovery is incomplete.6 In a
study of COPD patients with moderate-to-severe airflow
obstruction, recovery time became longer and symptoms
more frequent during an AECOPD as the disease progressed.3
Patients with sudden onset of AECOPD were found to have
more respiratory symptoms, but a shorter recovery time,
compared with those with gradual onset of AECOPD.7
The extent to which the addition of COPD maintenance
treatment to RTI treatment improves pulmonary function and
alters the trajectory of recovery in maintenance treatmentnaïve patients with COPD is unknown. Tiotropium, a longacting anticholinergic, has been shown to improve pulmonary
function, relieve symptoms, and reduce exacerbation frequency
1516
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in patients with stable COPD8–13 (ie, patients who were
exacerbation free for 4 or 6 weeks prior to randomization).
The Tiotropium In COPD patients with an Acute Respiratory Infection 1 (TICARI 1; ClinicalTrials.gov identifier:
NCT01483625) trial was conducted to evaluate the efficacy
and safety of tiotropium in maintenance treatment-naïve
patients with COPD presenting to the outpatient clinic with
symptoms of an acute RTI. Unfortunately, the study was
terminated early due to difficulties in patient recruitment,
resulting in inadequate statistical power to detect treatment
differences. However, the data collected provided an opportunity to examine the course of AECOPD from diagnoses to
week 12 in this little-studied patient population.

Methods
Original study design
TICARI 1 was a randomized, double-blind, placebo-controlled,
parallel-group, multicenter, Phase IV trial to evaluate the efficacy and safety of tiotropium in patients with acute RTI symptoms, who were either newly diagnosed with COPD at study
entry or had a previous diagnosis and maintenance treatment
naïve for $6 months pre-randomization. The study design is
detailed in Figure 1. The study was conducted in the United
States in primary care practices. Initial screening and case finding were carried out at visit 0 (Supplementary materials [Methods section]). Patients, meeting all inclusion and no exclusion
criteria, were randomized at visit 1 in a 1:1 ratio to tiotropium
bromide 18 μg or placebo, delivered via HandiHaler® (Boehringer Ingelheim, Ingelheim, Germany). Doses were self-administered once daily in the morning for 12 weeks, and patients
were followed for an additional 30±3 days from the last dose.
The target randomization sample size of 300 patients was not
achieved, despite an enrolment period extension, resulting
in inadequate power to achieve statistical significance in the
primary efficacy endpoint, trough forced expiratory volume
in 1 second (FEV1). Data from 140 subjects across treatment
groups were available for exploratory analyses.
The study was approved by Chesapeake Research Review,
Inc., Columbia, MD, USA (IRB00000790) and by the Institutional Review Board at the University of Kentucky, Lexington,
KY, USA (IRB00010346). All patients provided written
informed consent for study participation.

Sample
Study participants were male or female outpatients, aged $40
years, with a history of smoking ($100 cigarettes over their
lifetime) presenting to the clinic (outpatient setting) with
acute worsening respiratory symptoms consistent with RTI
for #7 days, including increase of previous or new shortness
International Journal of COPD 2018:13
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Figure 1 Study design.

of breath, or limitation of activities due to new/increased
shortness of breath; and at least one of the following:
1) increased chronic cough, new cough; 2) increased sputum
production and/or color change; 3) nasal symptoms (congestion, increased secretion, mucus amount, and/or color change);
4) new/increased wheeze; 5) breathing-related chest discomfort; 6) new/increased nighttime awakenings from respiratory
symptoms; 7) new/increased limitation of activities due to
respiratory symptoms; and 8) elevated temperature ($37.8°C)
at visit 0. AECOPD was defined as a patient-reported increase
or new onset of more than one of the following respiratory
symptoms: cough, sputum, sputum purulence, wheezing, and
dyspnea for $3 days with clinician assessment and treatment
with antibiotics and/or systemic steroids.
To confirm persistent airflow limitation, post-bronchodilator (four puffs of albuterol) FEV1/forced vital capacity
(FVC) ,0.7 was assessed via pulmonary function tests at
visit 1. In addition, a clinical assessment supporting both the
diagnosis of COPD and introduction of maintenance therapy
was required pre-randomization.
Key exclusion criteria included acute respiratory symptoms for .7 days pre-randomization; current asthma (subject
treated for asthma in the last 2 years), cystic fibrosis, clinical
diagnosis of bronchiectasis, interstitial lung disease, pulmonary thromboembolic disease, or significant disease other
than COPD; supplemental oxygen therapy for $24 consecutive hours during the 6 months pre-randomization; and
participation in a pulmonary rehabilitation program. Patients
were also excluded if they received COPD maintenance treatment during the 6 months pre-randomization; specifically,
therapy with any long-acting bronchodilator, short-acting
anticholinergic, inhaled corticosteroid, or maintenance use
of systemic corticosteroids for .14 consecutive days for
respiratory indications.
International Journal of COPD 2018:13

Patients were issued an electronic diary (eDiary [In2itive™
device; Vitalograph, Maids Moreton, UK]) at visit 1, to use
during the study.
During the study, patients received usual care for an
acute RTI, including antibiotics and/or oral corticosteroids.
They were also provided with rescue medication (open-label
albuterol hydrofluoroalkanes metered-dose inhaler), which
could be used at any time during the trial for symptom relief.
Only the albuterol provided by the trial sponsor was allowed
for rescue medication. Both study medication adherence and
rescue medication use were recorded daily in the eDiary.

Assessments

Pulmonary function testing
Spirometry was performed according to American Thoracic
Society/European Respiratory Society standards,14 and
predicted normal FEV1 values were calculated.15,16 Pre- and
post-bronchodilator pulmonary function tests were performed at visits 1 and 5. Peak expiratory flow rate (PEFR)
and FEV1 were measured by the patient every evening using
the integrated eDiary electronic peak flow meter. Spirometry
measurements at visits 1 and 5 were used for Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging17
(Supplementary materials [Methods section]).

EXACT
Patients completed the EXACT, a patient-reported outcome (PRO) measure, every evening in their eDiary prior
to bedtime. This diary asks patients to rate the severity
of 14 symptoms characteristic of an AECOPD, including
breathlessness, cough, sputum, chest symptoms, sleep
disturbance, feeling weak or tired, and feeling worried or
concerned.18 Scores range from 0 to 100, with higher scores
indicating a more severe health state.
submit your manuscript | www.dovepress.com
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EXACT daily scores were used to characterize the exacerbation symptom trajectory over time, including patterns of
recovery and relapse. Recovery was defined as a persistent,
sustained decrease in score (ie, improvement) $9 points
from the peak score observed during the first 14 days postrandomization, maintained for 7 consecutive days, using a
3-day rolling average beginning on Day 2. The first of the
7 days was set as the recovery day. Relapse, assessed in
patients who experienced a recovery, was defined as sustained worsening following recovery (increased EXACT
score $12 points for 2 consecutive days or $9 points for
3 consecutive days above the mean recovery value).19 For
evaluative purposes, EXACT change scores $5 points are
considered meaningful with sustained improvements of this
magnitude interpretable as recovering, although short of full
recovery as defined earlier.

Other PRO measures
The COPD Assessment Test™ (CAT),20 Functional Assessment of Chronic Illness Therapy–Short Form (FACIT-SF) for
dyspnea and functional limitation,21 and Work Productivity
and Activity Impairment Questionnaire: Respiratory Symptoms (WPAI:RS)22 were completed at visits 1–4.
The CAT20 is a disease-specific health status questionnaire.
The test has eight items assessing cough, phlegm (mucus)
production, chest tightness, breathlessness when going up
hills/stairs, activity limitation at home, confidence in leaving
home, sleep, and energy. Subjects rate each item on a scale of
0–5; item responses are summed to yield a total score ranging
from 0 to 40; where higher scores denote worse health status.
The minimum clinically important change score is estimated
to be 2 points,23 and a difference of 4.7 units between stable
and exacerbating patients with COPD has been reported.20
The FACIT-SF for dyspnea and functional limitation21
is a 20-item questionnaire with two components. One component assesses dyspnea severity over the past 7 days while
the second quantifies its effect on the performance of 10
common everyday tasks. For severity, patients rate their
dyspnea in relation to specific tasks, with scores ranging from
0 (no shortness of breath) to 3 (severely short of breath). For
functional limitation, patients describe how difficult it was to
perform the tasks, with scores ranging from 0 (no difficulty)
to 3 (much difficulty). For both the sections, if a task is not
undertaken because of dyspnea it is scored 3, otherwise it is
counted as a missing value. Raw scores for each section range
from 0 to 30, which are converted to scale scores (dyspnea,
27.7–75.9 and functional limitation, 29.7–76.7). The higher
the score the worse the dyspnea or functional limitation.
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The WPAI:RS22 assesses unpaid and paid work activity.
This questionnaire asks respondents to report time missed
from scheduled work due to respiratory symptoms, percentage of overall paid work impairment due to respiratory
symptoms, and the percentage of regular activities impairment due to respiratory symptoms (outside paid employment)
over the previous 7 days.

Safety and other assessments
Safety assessments included adverse event monitoring, physical examination, 12-lead electrocardiogram, and vital sign
assessments. Smoking status was assessed at all visits, and
concomitant medications taken #6 months before screening
and throughout the study were recorded.

Statistical analysis
Data from patients in both the treatment groups (n=140) were
pooled for analyses. Because the study was underpowered
for statistical testing, the primary analyses were descriptive.
Symptomatic change was examined weekly over time using
EXACT scores and rescue medication use; health status
(CAT), dyspnea (FACIT-SF), and functional limitation (FACIT-SF) were described at each clinic visit and change from
baseline calculated. Lost work days, work impairment, and
activity impairment over the 12-week treatment period were
also assessed (WPAI). To further understand the patterns of
symptomatic recovery, patients were stratified by symptomatic recovery status using the EXACT recovery rules (recovered without relapse, recovered and then relapsed, and failed
to meet the symptom improvement rule for recovery).
Categorical data are presented as number (%) and continuous data as mean (± standard deviation [SD]). Changes
from baseline are presented as mean ± SD and adjusted
mean changes from baseline as mean (± standard error [SE]).
Finally, exploratory logistic regression analyses were performed to assess the extent to which selected demographic
and clinical characteristics (age, sex, smoking status, baseline
FEV1, and treatment) may differentiate patients who recovered from those who did not recover and those who relapsed
from those who did not relapse.

Results
Study population
Of the 266 patients enrolled in the trial, 47.4% failed screening (Figure S1). The most frequent reason (77.8%) for
exclusion was failure to meet the trough FEV1/FVC ,0.70
criterion. Overall, 140 patients were randomized and treated
at 27 US centers. Treatment was completed by 95.7% of
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patients, with a mean ± SD study medication compliance
of 91.4%±13.2%. Study completion and compliance were
similar between the treatment groups.
Baseline demographics and clinical characteristics of the
analytical sample (N=140) and the recovery groups are shown
in Tables 1 and 2. Most of the patients (73.6%) had a prior
COPD diagnosis, and the date of prior diagnosis was known
for 42.1% of patients; for these patients, the mean ± SD COPD
duration was 1.05±1.75 years. The comorbidities experienced
by the study patients were typical of those seen in the general
COPD population, with the majority (97.9%) of patients having
$1 comorbid condition. All patients were COPD maintenance
treatment naïve prior to enrolment in the study. During the 3
months pre-randomization, short-term pulmonary (non-maintenance therapy) medications were taken by 16.4% of patients,
the most frequent were short-acting β2 agonists (SABA;
11.4%) and oral corticosteroids (5.0%); other pulmonary
medications were reported by ,3.0% of patients (Table S1).
Documentation of airflow obstruction and disease severity based on spirometry was obtained pre-randomization
(visit 1) and at the follow-up (visit 5). Spirometric values
were similar between visits, with most patients having GOLD
stage II COPD17 (visit 1: 54.3%; visit 5: 51.1%; Table 1). The
CAT20 and FACIT-SF for dyspnea and functional limitation21
scores indicated impaired health status at baseline.

Acute respiratory events and
management
Acute respiratory events at visit 0 pertained to the acute
symptoms that led to the patient’s clinic visit. Patients
reported a mean ± SD duration of acute RTI symptoms prerandomization of 3.9±1.7 days. Of the symptoms specified
as inclusion criteria, 80.0% of patients reported an increase
in shortness of breath, 18.6% new shortness of breath, and
78.6% limitation in daily activities due to new/increased
shortness of breath. The frequency of additional symptoms
are shown in Table S2. At baseline, 32.1% of patients met the
criteria for COPD exacerbation as defined in the protocol.
At baseline (pre-randomization), 13.6% of patients were
taking non-maintenance pulmonary medications; 11.4% were
taking prednisone; other pulmonary medications were reported
by ,2.0% of patients. (If a medication was started before
informed consent [visit 0] and ended at or after the date of
informed consent, it was considered as being used at baseline.)
Less than half of the patients (40.0%, n=56) reported
taking active treatment for their RTI (within the 7 days before
and after randomization). Of those who received treatment,
34.3% reported corticosteroids (primarily prednisone), 32.1%

International Journal of COPD 2018:13
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Table 1 Baseline demographics and clinical characteristics
Characteristics

Total group
(n=140)

Male/female, n (%)
Age, years, mean ± SD (range)
Age groups, n (%)
,55 years

63 (45.0)/77 (55.0)
58.0±8.7 (40–83)
60 (42.9)

55–65 years
.65 years

52 (37.1)
28 (20.0)

Race, n (%)
White
Black or African American
Other
Ethnicity, n (%)
Hispanic/Latino
Non-Hispanic/Latino

132 (94.3)
6 (4.3)
2 (1.4)
2 (1.4)
138 (98.6)

Body mass index, kg/m2, mean ± SD
Ex-smoker/current smoker, n (%)
Smoking history
Pack-years,a mean ± SD
$10 pack-years,a n (%)

27.8±7.1
34 (24.3)/106 (75.7)
46.3±30.9
132 (94.3)

Employed, n (%)

57 (40.7)

Post-bronchodilator spirometry (visit 1), mean ± SD
1.78±0.64
FEV1, L
62.71±19.10
FEV1, % predicted
FVC, L

3.20±0.97

FVC, % predicted

91.75±19.68

FEV1/FVC

0.56±0.10

Prior physician COPD diagnosis at study
entry, n (%)
COPD duration in patients with known date of
prior diagnosis (n/N=59/103), years, mean ± SD
GOLD stage (visit 1/visit 5b), n (%)
I (mild)
II (moderate)
III (severe)
IV (very severe)
Unclassifiedc
Patients with concomitant diagnosis,d n (%)
Hypertension
Hyperlipidemia
Depression
Anxiety
Gastroesophageal reflux disease
Osteoarthritis

103 (73.6)

CAT score, mean ± SD

23.8±7.6e

1.05±1.75

24 (17.1)/18 (13.7)
76 (54.3)/67 (51.1)
36 (25.7)/29 (22.1)
4 (2.9)/5 (3.8)
0 (0)/12 (9.2)
137 (97.9)
63 (45.0)
47 (33.6)
41 (29.3)
38 (27.1)
36 (25.7)
31 (22.1)

FACIT-SF – dyspnea score, mean ± SD
53.6±9.4f
FACIT-SF – functional limitation score, mean ± SD 51.6±9.8f
Notes: a1 pack-year represents 20 cigarettes per day for 1 year. bVisit 5:
n=131. cAt visit 1 (baseline), 12 patients had airflow obstruction determined by
spirometry, but on repeat spirometry at visit 5, they did not meet the GOLD
criteria for airflow obstruction and were therefore unclassified. dMedical
Dictionary for Drug Regulatory Activities (MedRA) version 15.1 preferred terms,
most frequently reported concomitant diagnoses ($20% of patients in either
treatment group); patients may be included in more than one preferred term.
e
n=98. fn=139.
Abbreviations: CAT, COPD Assessment Test™; FACIT-SF, Functional Assessment
of Chronic Illness Therapy–Short Form; FEV1, forced expiratory volume in 1 second;
FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung
Disease; SD, standard deviation.
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Table 2 Pre- and post-bronchodilator pulmonary function and
GOLD stage at visit 1 by exacerbation recovery pattern
Recovered
Recovered
No
without relapse then relapsed recovery
(n=69)
(n=41)
(n=30)

Pre-bronchodilator spirometry, mean ± SD
1.62±0.62
1.55±0.60
FEV1, L
56.11±19.75
FEV1, % predicted 57.32±19.52
2.95±0.98
2.89±1.04
FVC, L
85.43±24.23
FVC, % predicted 84.07±21.53
0.55±0.09
0.54±0.11
FEV1/FVC ratio
Post-bronchodilator spirometry, mean ± SD
1.77±0.63
1.67±0.61
FEV1, L
60.20±19.95
FEV1, % predicted 62.59±18.93
3.20±1.00
3.01±0.88
FVC, L
89.17±18.77
FVC, % predicted 91.51±20.50
0.55±0.09
0.55±0.11
FEV1/FVC ratio
GOLD stage, n (%)
I (mild)
10 (14)
6 (15)
II (moderate)
40 (58)
20 (49)
III (severe)
18 (26)
13 (32)
IV (very severe)
1 (1)
2 (5)

1.87±0.70
63.60±20.47
3.27±0.94
90.95±20.45
0.56±0.11
1.96±0.69
66.41±18.35
3.46±0.98
95.82±18.92
0.56±0.11
8 (27)
16 (53)
5 (17)
1 (3)

Symptomatic recovery and relapse

Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced
vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease;
SD, standard deviation.

were treated with antibiotics, and 5% were on SABAs.
Overall, the mean ± SD course of antibiotics was 7.2±2.7 days
(range 2–14 days; median 7.0 days).
Medication use and symptoms by treatment group are
shown in Tables S1 and S2, respectively, and results of the
exploratory efficacy analyses for the effect of treatment on
trough FEV1 and trough FVC are provided in Figure S2. Data
for mean daily FEV1 and PEFR are shown in Table S3.

Exacerbation recovery patterns
Over the 12 weeks of treatment, EXACT scores18 and rescue
medication use showed similar patterns. EXACT scores

%











The mean ± SD peak EXACT score during the first 14 days
of treatment was 49.7±12.1. Most of the patients (n=110,
78.6%) exhibited an initial pattern of symptomatic recovery,
with a mean recovery time from peak symptoms of 9.8 days
(median 5.0 days; range 2–61 days). Although the tiotropium group had a higher percentage of patients who initially
recovered compared with placebo (80.9% vs 76.4%) and a
shorter mean recovery time (8.7 vs 10.9 days), the study was
underpowered to detect a difference.
Mean ± SD weekly EXACT scores declined during the first
4 weeks following the initial clinic visit from 40.5±11.1 at week
1 to 35.9±12.4 at week 4; the mean at week 12 was 36.0±13.6
(Figure 2A). Mean ± SD weekly intraindividual variability in
the EXACT score showed a trend for reduction over time from
5.47±2.71 at week 1 to 3.66±2.74 at week 12.
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Characteristics

declined over time from baseline (Figure 2A), indicating
symptom improvement; the number of rescue medication
puffs also declined (Figure 2B).
Mean CAT scores declined (health status improved) over
time (Figure 3A). By week 2, the estimated minimum clinically
important difference of a change from baseline of 2 CAT points23
was reached (mean ± SD, -4.0±5.4) with continued improvement thereafter (Figure 3B). According to the FACIT-SF, there
were also trends for improvement in dyspnea (Figure 3C and
D) and functional limitation (Figure 3E and F) over time; at
week 12, mean ± SD changes from baseline were -5.3±8.2 for
dyspnea and −4.2±7.5 for functional limitation. Trends were
similar for the treatment groups (Figure S3A–F).
The 57 employed patients at baseline reported a mean ± SD
number of lost working days over the 12-week treatment period
of 5.23±8.45 days. Other WPAI:RS22 data are shown in Table S4.
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Figure 2 Weekly mean ± SE of daily (A) EXACT scores and (B) number of rescue medication puffs.
Notes: Shaded area represents the presumed pre-event mean ± SE, based on week 12 data. Solid line in A represents the 5-point change from the initial assessment.
Abbreviations: EXACT, EXAcerbation of Chronic Pulmonary Disease Tool; SE, standard error.
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Figure 3 Exacerbation recovery patterns.
Notes: Descriptive statistics (mean ± SD) for the CAT and FACIT – Short Form scores for dyspnea and functional limitation over time (A, C, and E, respectively) and change
from baseline (B, D, and F, respectively). For the CAT, only patients with COPD diagnosis before study entry were assessed.
Abbreviations: CAT, COPD Assessment Test™; FACIT, Functional Assessment of Chronic Illness Therapy; SD, standard deviation.

Of the 140 randomized patients, 49.3% (n=69) recovered without relapse, 29.3% (n=41) recovered and then
relapsed, and 21.4% (n=30) failed to meet the symptom
improvement rule for recovery. Of the 110 patients who
initially recovered, most (62.7%, n=69) remained stable
during the 12-week study period. The pattern of recovery
is supported by other objective indicators of relapse, collected during the 12-week treatment period, including the
frequency of follow-up visits for acute worsening of COPD
(25.7%), a second exacerbation (12.9%), or escalation of
therapy (3.6%).
International Journal of COPD 2018:13

In patients who recovered with no relapse, the daily mean
EXACT score declined (improved) from baseline to around
week 3, thereafter remaining relatively stable to week 12
(Figure 4A). In contrast, patients who recovered and then
relapsed (Figure 4B) or did not recover (Figure 4C) had
more variable patterns of EXACT scores over the course of
the 12-week treatment period.
The percentages of patients taking non-maintenance
pulmonary medications within 3 months of study enrollment
were 13.0% in the recovered without relapse group, 9.8%
in the recovered and then relapsed group, and 20.0% in the
submit your manuscript | www.dovepress.com
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Figure 4 Daily EXACT scores (mean ± SE).
Notes: (A) Patients who recovered without a subsequent relapse (n=69), (B) patients who recovered and then relapsed (n=41), and (C) patients who did not meet the
symptom improvement rule for recovery (n=30).
Abbreviations: EXACT, EXAcerbation of Chronic Pulmonary Disease Tool; SE, standard error.

group who failed to meet the symptom improvement rule for
recovery. In the 14 days prior to randomization, 33.6% of
patients received treatment for their respiratory symptoms
(31.9% in the recovered without relapse group; 29.3% in
the recovered and then relapsed group, and 43.3% in the
group who failed to meet the symptom improvement rule
for recovery).
At baseline, 32.1% of patients met the criteria for a
COPD exacerbation as defined in the protocol. In this subgroup, the percentages of patients in each of the recovery
groups were similar (recovered without relapse, 31.9%;
recovered and then relapsed, 31.7%; and failed to meet the
symptom improvement rule for recovery, 33.3%).
Exploratory logistic regression analyses suggested poor
model fit for both recovery status (likelihood ratio chi-square
4.39; P=0.49) and relapse status (likelihood ratio chi-square
5.48; P=0.36) with no apparent signals for individual parameters (lowest significance (P) levels: 0.18 for FEV1 recovery
status model and 0.12 for treatment relapse status model).

Safety
No deaths were reported. Overall, 44.3% of patients reported
adverse events; 41.2% on tiotropium; and 47.2% on placebo.
No clinically notable mean changes in vital sign measurements
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occurred, and no trends were observed. During the study,
six patients (4.3%; three patients per treatment group) had
serious adverse events that required hospitalization. Further
safety data are provided in Supplementary materials (Safety
section) and Table S5.

Discussion
TICARI 1 aimed to assess the efficacy and safety of tiotropium maintenance therapy compared with placebo in patients
seen in an outpatient clinic with symptoms of an acute RTI,
who were either newly diagnosed with COPD or had a prior
COPD diagnosis but were maintenance treatment naïve. Due
to recruitment difficulties, the study was underpowered to
detect treatment differences. Descriptive data suggest that
tiotropium was well-tolerated and showed an overall trend
for clinical benefit. Data were pooled across treatment groups
for an exploratory analysis of AECOPD recovery patterns
in this little-studied patient group.
As a group, these maintenance treatment-naïve or newly
diagnosed patients with COPD experienced symptomatic
improvement over the study period with consistent patterns
across outcome measures. Mean time from peak symptoms to
recovery was 9.8 days (median, 5.0 days). These results are
within the total symptom score recovery estimate for return
International Journal of COPD 2018:13
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to baseline (exacerbation onset) of 7 days (interquartile range,
4–14 days), reported by Seemungal et al,6 and are shorter
than the AECOPD recovery times of 11–13 days reported
by Aaron et al.7
Half of the patients in this sample either relapsed or failed
to meet the criteria for symptomatic recovery with persistent
elevated symptoms at week 12. In the group of patients who
did not recover, a higher percentage (43.3%) had received
treatments for their respiratory symptoms in the 14 days prior
to randomization than patients who recovered without relapse
(31.9%) and those who recovered and then relapsed (29.3%).
Exploratory analysis showed that age, sex, smoking status,
baseline FEV1, or treatment assignment was not associated
with recovery or relapse status.
Relapse and persistent symptoms with AECOPD in
diagnosed patients treated for COPD have been reported
previously. Beauchesne et al24 reported a 29.5% failure
rate with antibiotic treatment for AECOPD within 30 days
from start of treatment. The study by Seemungal et al6 in
COPD patients with moderate-to-severe airflow obstruction
showed that recovery from an AECOPD was incomplete in
a “significant proportion” of patients and suggested that, following ambulatory treatment for an AECOPD, relapse rates
are 20%–25%.25 In our study of COPD patients who were
maintenance treatment naïve, 29% of patients recovered and
then relapsed and another 21% showed patterns consistent
with persistent symptoms over 12 weeks. Symptom persistence after an AECOPD has been associated with systemic
inflammation.26 Furthermore, the presence of an AECOPD
increases a patient’s susceptibility to having another, particularly in the high-risk period immediately following an
AECOPD.27,28 Medical treatment of AECOPD events that
includes pharmacologic therapy, patient education, and
early follow-up treatment in cases of symptomatic relapse
may reduce AECOPD frequency and improve short- and
long-term outcomes.29
Although the mean peak EXACT score during the first
14 days of treatment of 49.7±12.1 was similar to values seen
in the original validation study for the EXACT (47.9±9.6 on
day 1),18 it is lower than peak values observed in studies of
moderate-to-severe COPD patients diagnosed and treated
as outpatients for AECOPD (53.3±10.0 to 56.8±12.3),19
suggesting that the undiagnosed and untreated patients in
the current study were experiencing milder exacerbations
with less room for improvement. It is possible that the
9-point threshold to define recovery using the EXACT may
be too stringent in milder patients or milder cases of RTI.
At week 12, patients, on average, were symptomatic, with
mean EXACT scores of 36.0±13.6 and mean CAT scores
International Journal of COPD 2018:13

Exacerbation recovery/relapse: COPD with acute RTI

of 17.3±8.0, similar to values for stable patients reported
previously.18,19 These results suggest that patients were
symptomatic with impaired health status when stable and
may have benefited from maintenance therapy.
Over half of the patients were GOLD stage II;17 many
patients with mild airway obstruction may not seek medical
attention, unless their symptoms impact their daily lives,30
and many fail to seek medical attention for AECOPD.31 Previous studies of maintenance treatment-naïve patients with
GOLD stage II COPD have shown improved lung function
and reduced AECOPD risk when treated with tiotropium
maintenance therapy.32,33 Pulmonary function testing at the
time the patient is seen in the clinic for acute RTI symptoms
is one approach for identifying undiagnosed cases of COPD
and initiating patient education and maintenance therapy.
Although our study was underpowered to detect treatment
differences, numerical improvements in lung function and the
trend toward shorter recovery time with tiotropium compared
with placebo suggest that further study is warranted. Whether
treatment initiation in newly diagnosed or treatment-naïve
patients at the time of an acute RTI will lead to a reduction
in risk of future AECOPD also needs evaluation. Previous
research suggests this may be the case.34–37
The study had some limitations. Patients included in
the study presented with symptoms of acute RTI and were
evaluated clinically; however, no laboratory tests for specific
pathogens were performed. At visit 1 (baseline), 12 patients
had airflow obstruction determined by spirometry, but on
repeat spirometry at visit 5, they did not meet the GOLD criteria for airflow obstruction and were therefore unclassified.
The patients had to demonstrate obstruction after four puffs of
albuterol, thus excluding those patients with mild RTI-related
bronchoconstriction. Patients with a history of smoking $100
cigarettes over their lifetime was considered an inclusion criteria; however, this level of smoking could be considered mild,
as generally most patients thought to be at risk of COPD have
a $10 pack-year smoking history. In this study, the proportion
of patients with a ,10 pack-year smoking history was only
5.7%. Furthermore, no association between smoking status
(active vs former) and recovery status was observed.
Further investigation on the initiation of maintenance
therapy in newly diagnosed or treatment-naïve patients and
patterns of recovery from exacerbations in this population
is warranted.

Conclusion
AECOPD recovery time for these newly diagnosed and
maintenance treatment-naïve patients was at least 5 days, with
around half experiencing relapse or persistent symptoms over
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the 12-week follow-up. Further investigations are required to
determine whether initiating COPD maintenance therapy during an AECOPD could improve short- and long-term outcomes
and reduce the risk of future AECOPD in this population.
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